|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10,520.00 GBX | -0.27% |
|
-4.70% | +0.42% |
| 06-02 | ASTRAZENECA : Buy rating from JP Morgan | ZD |
| 06-02 | UK's FTSE 100 closes around flat as staples, healthcare losses eclipse energy gains | RE |
Company Valuation: AstraZeneca PLC
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 131,259 | 182,034 | 209,442 | 209,268 | 203,171 | 220,359 | - | - |
| Change | - | 38.68% | 15.06% | -0.08% | -2.91% | 8.46% | - | - |
| Enterprise Value (EV) 1 | 143,126 | 206,417 | 232,365 | 231,778 | 227,741 | 240,622 | 233,236 | 223,429 |
| Change | - | 44.22% | 12.57% | -0.25% | -1.74% | 5.66% | -3.07% | -4.2% |
| P/E ratio | 41x | 1,469x | 64.1x | 35.4x | 29.1x | 22.3x | 18.5x | 16.2x |
| PBR | 8.4x | 4.24x | 5.65x | 5.39x | 5.02x | 4.92x | 4.29x | 3.69x |
| PEG | - | -15.2x | 0x | 0.4x | 1.6x | 0.5x | 0.9x | 1.2x |
| Capitalization / Revenue | 4.93x | 4.87x | 4.72x | 4.57x | 3.76x | 3.81x | 3.6x | 3.41x |
| EV / Revenue | 5.38x | 5.52x | 5.24x | 5.06x | 4.21x | 4.16x | 3.81x | 3.46x |
| EV / EBITDA | 17.2x | 27.2x | 25.2x | 17.1x | 13.6x | 12.2x | 10.3x | 9.03x |
| EV / EBIT | 19.5x | 20.8x | 17.4x | 15.9x | 13.5x | 13x | 11.2x | 9.76x |
| EV / FCF | 37.3x | 42.4x | 26.7x | 25.8x | 22.9x | 31.6x | 18.4x | 15.6x |
| FCF Yield | 2.68% | 2.36% | 3.75% | 3.88% | 4.36% | 3.16% | 5.45% | 6.42% |
| Dividend per Share 2 | 2.8 | 2.87 | 2.9 | 2.9 | 3.1 | 3.213 | 3.376 | 3.535 |
| Rate of return | 2.8% | 2.44% | 2.15% | 2.15% | 2.37% | 2.26% | 2.38% | 2.49% |
| EPS 2 | 2.44 | 0.08 | 2.11 | 3.81 | 4.5 | 6.384 | 7.694 | 8.775 |
| Distribution rate | 115% | 3,588% | 137% | 76.1% | 68.9% | 50.3% | 43.9% | 40.3% |
| Net sales 1 | 26,617 | 37,417 | 44,351 | 45,811 | 54,073 | 57,830 | 61,182 | 64,582 |
| EBITDA 1 | 8,311 | 7,586 | 9,237 | 13,580 | 16,691 | 19,647 | 22,555 | 24,743 |
| EBIT 1 | 7,340 | 9,928 | 13,350 | 14,534 | 16,928 | 18,538 | 20,755 | 22,887 |
| Net income 1 | 3,196 | 112 | 3,288 | 5,961 | 7,035 | 9,919 | 11,947 | 13,392 |
| Net Debt 1 | 11,867 | 24,383 | 22,923 | 22,510 | 24,570 | 20,263 | 12,878 | 3,070 |
| Reference price 2 | 99.99 | 117.51 | 135.16 | 135.02 | 131.05 | 142.11 | 142.11 | 142.11 |
| Nbr of stocks (in thousands) | 1,312,660 | 1,549,159 | 1,549,528 | 1,549,926 | 1,550,317 | 1,550,658 | - | - |
| Announcement Date | 11/02/21 | 10/02/22 | 09/02/23 | 08/02/24 | 06/02/25 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 22.26x | 4.16x | 12.25x | 2.26% | 220B | ||
| 37.02x | 12.25x | 27.87x | 0.76% | 705B | ||
| 14.44x | 4.02x | 11.08x | 3.47% | 363B | ||
| 18.41x | 6.64x | 13.24x | 2.73% | 331B | ||
| 27.74x | 6.38x | 13.29x | 3.53% | 328B | ||
| 14.17x | 3.47x | 8.61x | 3.81% | 254B | ||
| 16.73x | 4.49x | 10.83x | 3.4% | 228B | ||
| 10.16x | 3.3x | 7.11x | 4.06% | 199B | ||
| 21.47x | 5.7x | 11.05x | 3.31% | 156B | ||
| 11.22x | 2.79x | 6.9x | 7.15% | 136B | ||
| Average | 19.36x | 5.32x | 12.22x | 3.45% | 291.92B | |
| Weighted average by Cap. | 22.51x | 6.55x | 15.01x | 2.88% |
Year-on-year evolution of the PER
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- AZN Stock
- Valuation AstraZeneca PLC
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition